RJFSA
TEVA icon

Raymond James Financial Services Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.08M Sell
59,707
-4,996
-8% -$87.4K ﹤0.01% 2116
2024
Q2 		$1.05M Sell
64,703
-413
-0.6% -$6.36K ﹤0.01% 2055
2024
Q1 		$919K Sell
65,116
-7,810
-11% -$98.4K ﹤0.01% 2125
2023
Q4 		$761K Sell
72,926
-787
-1% -$7.35K ﹤0.01% 2147
2023
Q3 		$752K Sell
73,713
-776
-1% -$7.23K ﹤0.01% 2074
2023
Q2 		$561K Sell
74,489
-18,775
-20% -$152K ﹤0.01% 2281
2023
Q1 		$825K Sell
93,264
-5,664
-6% -$56K ﹤0.01% 2031
2022
Q4 		$902K Sell
98,928
-1,466
-1% -$12.8K ﹤0.01% 1905
2022
Q3 		$810K Sell
100,394
-25,599
-20% -$226K ﹤0.01% 1946
2022
Q2 		$947K Buy
125,993
+9,858
+8% +$85.9K ﹤0.01% 1876
2022
Q1 		$1.09M Buy
116,135
+8,330
+8% +$69.5K ﹤0.01% 1884
2021
Q4 		$864K Sell
107,805
-43,955
-29% -$397K ﹤0.01% 2065
2021
Q3 		$1.48M Sell
151,760
-152,111
-50% -$1.42M ﹤0.01% 1680
2021
Q2 		$3.01M Sell
303,871
-290,358
-49% -$3.07M 0.01% 1247
2021
Q1 		$6.86M Buy
594,229
+26,194
+5% +$300K 0.02% 757
2020
Q4 		$5.48M Buy
568,035
+15,825
+3% +$152K 0.01% 796
2020
Q3 		$4.97M Buy
552,210
+62,782
+13% +$664K 0.01% 763
2020
Q2 		$6.04M Buy
489,428
+25,279
+5% +$286K 0.02% 634
2020
Q1 		$4.17M Buy
464,149
+103,888
+29% +$1.06M 0.02% 586
2019
Q4 		$3.53M Buy
360,261
+126,836
+54% +$1.13M 0.01% 869
2019
Q3 		$1.61M Sell
233,425
-8,530
-4% -$65.4K 0.01% 1223
2019
Q2 		$2.23M Buy
241,955
+182,523
+307% +$2.2M 0.01% 1046
2019
Q1 		$932K Sell
59,432
-16,755
-22% -$295K ﹤0.01% 1498
2018
Q4 		$1.18M Buy
76,187
+1,497
+2% +$30.7K 0.01% 1178
2018
Q3 		$1.61M Sell
74,690
-8,783
-11% -$204K 0.01% 1199
2018
Q2 		$2.03M Buy
83,473
+16,946
+25% +$346K 0.01% 1017
2018
Q1 		$1.14M Sell
66,527
-2,031
-3% -$39.7K 0.01% 1233
2017
Q4 		$1.3M Sell
68,558
-7,520
-10% -$113K 0.01% 1140
2017
Q3 		$1.34M Sell
76,078
-83,555
-52% -$1.88M 0.01% 1124
2017
Q2 		$5.3M Buy
159,633
+15,038
+10% +$465K 0.04% 491
2017
Q1 		$4.64M Buy
144,595
+37,692
+35% +$1.29M 0.04% 510
2016
Q4 		$3.88M Sell
106,903
-34,758
-25% -$1.39M 0.03% 521
2016
Q3 		$6.52M Buy
141,661
+29,016
+26% +$1.51M 0.06% 361
2016
Q2 		$5.66M Buy
112,645
+15,635
+16% +$832K 0.05% 375
2016
Q1 		$5.19M Buy
97,010
+7,417
+8% +$435K 0.06% 347
2015
Q4 		$5.88M Buy
89,593
+6,661
+8% +$412K 0.07% 324
2015
Q3 		$4.68M Buy
+82,932
New +$5.38M 0.08% 299
2013
Q4 		– Sell
-11,647
Closed -$440K – 522
2013
Q3 		$440K Sell
11,647
-55,112
-83% -$2.15M 0.03% 418
2013
Q2 		$2.62M Buy
+66,759
New +$2.6M 0.08% 310

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Raymond James Financial Services Advisors's TEVA Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 7.7% in Q3 2024, selling an estimated $87.4K and leaving 59,707 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

Raymond James Financial Services Advisors first reported a position in TEVA in Q2 2013 and has held it in 39 quarters since. The position peaked at $6.86M in Q1 2021. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Raymond James Financial Services Advisors held 59,707 shares of Teva Pharmaceuticals worth $1.08M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 4,996 Teva Pharmaceuticals shares in Q3 2024, an estimated $87.4K.
  • Teva Pharmaceuticals made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2116 holding.
  • Raymond James Financial Services Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
  • Raymond James Financial Services Advisors's Teva Pharmaceuticals position peaked at $6.86M in Q1 2021.
  • 543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.